Optimizing long-term therapy for Parkinson disease: Levodopa, dopamine agonists, and treatment-associated dyskinesia

Clinical Neuropharmacology

Volumn 31, Issue 1, 2008, Pages 51-56

  Stacy, Mark ^a   Galbreath, Andrew ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopamine agonist; Dyskinesia; Levodopa; Parkinson disease

Indexed keywords

CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

AGITATION; ANXIETY DISORDER; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; DYSPNEA; DYSTONIA; EDEMA; GASTRITIS; GASTROINTESTINAL SYMPTOM; GENERALIZED EDEMA; HALLUCINATION; HEADACHE; HERNIA; HUMAN; HYPOTENSION; LONG TERM CARE; MIGRAINE; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; SEXUAL DEVIATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; VALVULAR HEART DISEASE; VOMITING;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 40049107958     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318065b088     Document Type: Article

References (25)

1. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. 2004;19:997-1005.
2. Factor SA. Parkinson's disease: initial treatment with levodopa or dopamine agonists. Curr Treat Options Neurol. 2001;3:479-493.
3. Olanow CW. The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology. 2002;58(4 suppl 1):33-41.
4. Schwarz J. Rationale for dopamine agonist use as monotherapy in Parkinson's disease. Curr Opin Neurol. 2003;16(suppl 1):27-33.
5. Rinne UK, Bracco F, Chouza C, et al. The PKDS009 Study Group. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs. 1998;55(suppl 1):23-30.
6. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
7. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
8. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging. 2003;20:847-855.
9. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(11 suppl 5):1-88.
10. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
11. Mondal BK, Suri S. Pergolide-induced retroperitoneal fibrosis. Int J Clin Pract. 2000;54:403.
12. Varsano S, Gershman M, Hamaoui E. Pergolide-induced dyspnea, bilateral pleural effusion and peripheral edema. Respiration. 2000;67:580-582.
13. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62:1377-1381.
14. Van Camp G, Flamez A, Cosyns B, et al. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 2003;61:859-861.
15. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179-1183.
16. Ferreira JJ, Galitzky M, Montastruc JL, et al. Sleep attacks and Parkinson's disease treatment. Lancet. 2000;355:1333-1334.
17. Kruger TH, Haake P, Haverkamp J, et al. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol. 2003;179:357-365.
18. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease. Neurology. 2006;67:1225-1229.
19. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Eng J Med. 2007;356:29-38.
20. Pinero A. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med. 2005;353:1976-1977.
21. Martin M, Iglesias-Cubero G, Molina B, et al. Mitral heart disease due to cabergoline. Int J Cardiol. 2007;114:E7-E8.
22. Hubble JP. Long-term studies of dopamine agonists. Neurology. 2002;58(4 suppl 1):42-50.
23. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93-101.
24. Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur J Neurol. 2002;9(suppl 3):15-22.
25. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18:733-746.